AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 18702964
Drug: Moderate LDL-C
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Moderate LDL-C lowering with lovastatin 2.5 to 5 mg/day (target LDL-C of 130 to 140 mg/dl)
Trial: 18574557
Drug: Motesanib diphosphate
RxNorm normalized name: trisodium diphosphate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Motesanib diphosphate 50 mg once daily from day 1 through 15 with ketoconazole 400 mg on day 8 (n=7)
Trial: 18574557
Drug: Motesanib diphosphate
RxNorm normalized name: trisodium diphosphate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Motesanib diphosphate 125 mg once daily after day 16 (n=13)
Trial: 9309995
Drug: Oral nutritional
RxNorm normalized name: Ocean Blue Nutritionals Omega-3 1450 Oral Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral nutritional supplementation (10 kcal/kg/d)
Trial: 24700403
Drug: Clevidipine (0.2-8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clevidipine (0.2-8 μg·kg(‐1)·min(‐1))
Trial: 24700403
Drug: Nitroglycerin (NTG)
DrugBank: Nitroglycerin (DB00727)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nitroglycerin (NTG) (0.4 μg·kg(‐1)·min(‐1) to a clinician‐determined maximum dose)
Trial: 19230981
Drug: Aripiprazole (15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aripiprazole (15 mg/day, 20 mg/day, or 30 mg/day)
Trial: 15584487
Drug: IFN-beta treatment
RxNorm normalized name: PEG IFN-beta-1a
DrugBank: Peginterferon beta-1a (DB09122)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: IFN-beta treatment
Trial: 11425410
Drug: Reteplase alone
RxNorm normalized name: reteplase
DrugBank: Reteplase (DB00015)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Reteplase alone (standard-dose)
Trial: 11425410
Drug: Reteplase plus
RxNorm normalized name: reteplase
DrugBank: Reteplase (DB00015)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Reteplase plus abciximab (half-dose reteplase and full-dose abciximab)
Trial: 8037103
Drug: 5 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg torsemide
Trial: 8111802
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg torsemide
Trial: 8111802
Drug: 20 mg
RxNorm normalized name: urea 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg torsemide
Trial: 27185372
Drug: 500 mg
RxNorm normalized name: bran 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 500 mg fulvestrant
Trial: 18356332
Drug: Macadamia nut-rich
RxNorm normalized name: Macadamia nut
DrugBank: Macadamia nut (DB10655)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Macadamia nut-rich diet (42.5 g, 1.5 ounces, 33% total fat; 7% SFA, 18% MUFA, 5% PUFA)
Trial: 12519049
Drug: Tibolone added
RxNorm normalized name: TIBOLONE
DrugBank: Tibolone (DB09070)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tibolone added to monthly triptoreline (3.75 mg every 28 days IM) treatment for six months.
Trial: 12519049
Drug: Monthly triptoreline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Monthly triptoreline (3.75 mg every 28 days IM) treatment for six months.
Trial: 12519049
Drug: Tibolone added
RxNorm normalized name: TIBOLONE
DrugBank: Tibolone (DB09070)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tibolone added to triptoreline treatment.
Trial: 12519049
Drug: Triptoreline treatment.
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triptoreline treatment.
Trial: 7497668
Drug: Enoxaparin 30
RxNorm normalized name: ENOXAPARIN 30MG/0.3ML INJ
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enoxaparin 30 mg subcutaneous every 12 hours
Trial: 7497668
Drug: Unfractionated heparin
RxNorm normalized name: Unfractionated heparin
DrugBank: Heparin (DB01109)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Unfractionated heparin 5000 units subcutaneous every 8 hours
Trial: 19803002
Drug: Ceftazidime 500
RxNorm normalized name: ceftazidime 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ceftazidime 500 mg
Trial: 19803002
Drug: Ceftazidime 500
RxNorm normalized name: ceftazidime 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ceftazidime 500 mg or 1 g
Trial: 28822576
Drug: Intravenous pembrolizumab
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous pembrolizumab every 2 weeks (n=279)
Trial: 28822576
Drug: Intravenous pembrolizumab
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous pembrolizumab every 3 weeks (n=277)
Trial: 28822576
Drug: Intravenous ipilimumab
RxNorm normalized name: Ipilimumab
DrugBank: Ipilimumab (DB06186)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Intravenous ipilimumab every 3 weeks (n=278)
Trial: 19805702
Drug: Cocaine vaccine
RxNorm normalized name: Cocaine
DrugBank: Cocaine (DB00907)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cocaine vaccine (succinylnorcocaine linked to recombinant cholera toxin B-subunit protein)
Trial: 11177086
Drug: Intramuscular ceftriaxone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramuscular ceftriaxone followed by 10 days of oral trimethoprim-sulfamethoxazole (IM + PO group)
Trial: 11177086
Drug: Oral trimethoprim-sulfamethoxazole
RxNorm normalized name: sulfamethoxazole / trimethoprim
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral trimethoprim-sulfamethoxazole alone (PO group)
Trial: 9353802
Drug: 10-mg controlled
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10-mg controlled release oxybutynin tablet
Trial: 9353802
Drug: 5-mg conventional
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5-mg conventional oxybutynin tablet
Trial: 8216445
Drug: Single oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single oral dose of mosapride citrate (5 mg, 10 mg, 20 mg, 40 mg)
Trial: 8216445
Drug: Multiple oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multiple oral dose of mosapride citrate (20 mg t.i.d. for one day, 10 mg t.i.d. for 8 days)
Trial: 8216445
Drug: Single oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single oral dose of mosapride citrate (10 mg) with food effect
Trial: 2957416
Drug: Ipratropium bromide
RxNorm normalized name: Ipratropium Bromide
DrugBank: Ipratropium (DB00332)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ipratropium bromide nasal spray (20 micrograms per spray, two sprays in each nasal cavity, four times daily for 3 weeks)
Trial: 7751529
Drug: Ipratropium bromide
RxNorm normalized name: Ipratropium Bromide
DrugBank: Ipratropium (DB00332)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ipratropium bromide nasal spray
Trial: 31313942
Drug: Dacomitinib (45
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dacomitinib (45 mg once-daily, with dose reductions to 30 mg and 15 mg QD)
Trial: 21844547
Drug: Oseltamivir, 75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oseltamivir, 75 mg twice daily
Trial: 21844547
Drug: Maxingshigan-yinqiaosan decoction,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Maxingshigan-yinqiaosan decoction, 200 mL 4 times daily
Trial: 18998193
Drug: Aspirator retractor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirator retractor used during socket preparation and cementation
Trial: 16430545
Drug: 6 mg
RxNorm normalized name: boron 6 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6 mg of isobaric bupivacaine
Trial: 16430545
Drug: 7 mg
RxNorm normalized name: pectin 7 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 7 mg of isobaric bupivacaine
Trial: 16430545
Drug: 8 mg
RxNorm normalized name: alloin 8 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 8 mg of isobaric bupivacaine
Trial: 16430545
Drug: 9 mg
RxNorm normalized name: fiber 469 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 9 mg of isobaric bupivacaine
Trial: 16430545
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg of isobaric bupivacaine
Trial: 16430545
Drug: 12 mg
RxNorm normalized name: pectin 12 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 12 mg of isobaric bupivacaine
Trial: 9282235
Drug: Nebulized L-NAME
RxNorm normalized name: L-NAME
DrugBank: N-omega-nitro-L-arginine methyl ester (DB12750)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nebulized L-NAME (15 mg in saline)
Trial: 8356861
Drug: Omeprazole (80
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omeprazole (80 mg orally)
Trial: 8356861
Drug: Ranitidine (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ranitidine (300 mg orally)
Trial: 8356861
Drug: Control (no
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (no antacid therapy)
Trial: 3041822
Drug: Uniphyl tablets
RxNorm normalized name: Uniphyl Tablets 400 MG Extended Release Oral Tablet
DrugBank: Theophylline (DB00277)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Uniphyl tablets administered once daily at bedtime
Trial: 3041822
Drug: Theo-Dur tablets
DrugBank: Theophylline (DB00277)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Theo-Dur tablets administered twice daily
Trial: 26791440
Drug: Schema therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Schema therapy (ST) training with peer supervision and limited expert supervision after a 4-day training.
Trial: 19563648
Drug: N-acetylcysteine (NAC)
DrugBank: Acetylcysteine (DB06151)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: N-acetylcysteine (NAC) 600 mg BID, starting 24 h before the procedure
Trial: 16226012
Drug: DHA supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DHA supplementation (algal oil providing 50 mg of DHA per kilogram per day for 6 months)
Trial: 8420684
Drug: Chemotherapy regimens
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy regimens (five different regimens)
Trial: 3510820
Drug: Inhaled metaproterenol
RxNorm normalized name: metaproterenol Inhalation Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled metaproterenol (1.30 mg six times a day)
Trial: 3510820
Drug: Sustained-release theophylline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sustained-release theophylline (plasma levels of 10-15 micrograms/ml)
Trial: 3510820
Drug: Combined drug
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined drug therapy (metaproterenol + theophylline)
Trial: 28894067
Drug: Empowerment Education
RxNorm normalized name: reductic acid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Empowerment Education Program (EEP) for kidney transplant patients, conducted weekly for six weeks
Trial: 15764050
Drug: Ultrasound rated
RxNorm normalized name: tacrolimus
DrugBank: Tacrolimus (DB00864)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ultrasound rated at 1 W/cm(2) with compressive therapy (Group A)
Trial: 15764050
Drug: Ultrasound rated
RxNorm normalized name: tacrolimus
DrugBank: Tacrolimus (DB00864)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ultrasound rated at 0.5 W/cm(2) with compressive therapy (Group B)
Trial: 15764050
Drug: Topical pharmacological
RxNorm normalized name: COPD pharmacologic substance
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical pharmacological treatment (Group C)
Trial: 12198045
Drug: Magnesium sulfate,
RxNorm normalized name: MAGNESIUM SULFATE,ANHYDROUS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Magnesium sulfate, 2.48 mmol, injected 20 s before propofol administration
Trial: 10536243
Drug: Witepsol H15
RxNorm normalized name: Witepsol H15 for Compounding
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Witepsol H15 (fast drug-releasing suppository)
Trial: 10536243
Drug: Witepsol W35
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Witepsol W35 (slow drug-releasing suppository)
Trial: 7763215
Drug: Isolutrol 0.15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Isolutrol 0.15 g/100 mL (Ketsugo)
Trial: 2145499
Drug: 5% benzoyl
RxNorm normalized name: BENZOYL PEROXIDE 2.5 g in 100 mL TOPICAL SOAP [Benzoyl Acne Wash -2.5% Benzoyl Peroxide]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5% benzoyl peroxide lotion
Trial: 9106905
Drug: ondansetron (0.15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ondansetron (0.15 mg/kg)
Trial: 27565521
Drug: Pretransplantation Cancer
RxNorm normalized name: Cancer/testis antigen 1
DrugBank: Cancer/testis antigen 1 (DB19291)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pretransplantation Cancer and Treatment Distress (CTXD)
Trial: 24474520
Drug: Auscultation technique
RxNorm normalized name: zinc pyrithione
DrugBank: Pyrithione (DB06815)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Auscultation technique using a standard stethoscope over the catheter insertion site after injecting 2 mL of NaCl 0.9% solution.
Trial: 24474520
Drug: Subcutaneous injections
RxNorm normalized name: immune globulin subcutaneous (human) - klhw Injection [Xembify]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous injections (control group) in the opposite arm.
Trial: 23346249
Drug: Continued treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continued treatment for another 7 days
Trial: 23346249
Drug: No treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No treatment for the next 7 days
Trial: 20922911
Drug: Levofloxacin (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Levofloxacin (500 mg/daily)
Trial: 9442783
Drug: Topical dorzolamide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical dorzolamide (3 times daily)
Trial: 9442783
Drug: Oral acetazolamide
RxNorm normalized name: Acetazolamide
DrugBank: Acetazolamide (DB00819)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral acetazolamide 250 mg (single administration)
Trial: 7734461
Drug: Usual care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Usual care plus frequent urine testing and acupuncture treatments
Trial: 25245776
Drug: Scrambler therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Scrambler therapy for up to ten daily 30‐min sessions
Trial: 19950325
Drug: High-intensity progressive
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-intensity progressive resistance training (PRT) for 24 weeks, twice weekly
Trial: 15478851
Drug: Proton pump
RxNorm normalized name: Proton pump inhibitor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Proton pump inhibitor treatment for 4 weeks
Trial: 9407268
Drug: Subjects' report
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects' report of exposure treatment undertaken at home
Trial: 7624106
Drug: 99Tcm-sestamibi (MIBI)
RxNorm normalized name: 99mTc sestamibi
DrugBank: Technetium Tc-99m sestamibi (DB09161)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 99Tcm-sestamibi (MIBI) injection for SPET imaging
Trial: 31175001
Drug: Quizartinib (60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Quizartinib (60 mg orally once daily, with a 30 mg lead-in)
Trial: 31175001
Drug: Chemotherapy (investigator's
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy (investigator's choice including low-dose cytarabine, mitoxantrone, etoposide, and others)
Trial: 26692084
Drug: Magnesium sulfate
RxNorm normalized name: Magnesium Sulfate
DrugBank: Magnesium (DB14513)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Magnesium sulfate (65 mg elemental magnesium) twice per day
Trial: 26692084
Drug: Placebo twice
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo twice per day
Trial: 27429174
Drug: Pain-contingent treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pain-contingent treatment as usual (TAU)
Trial: 17342074
Drug: High-energy yogurt
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-energy yogurt preload beverage (YP: 500 ml, 1988 kJ for men; 375 ml, 1507 kJ for women)
Trial: 15494230
Drug: Salivary amylase
RxNorm normalized name: Salivary amylase
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Salivary amylase activity monitor using a testing-strip and optical analyzer measuring salivary amylase activity with a range of 0-200 kU/l within 150 s.
Trial: 11341354
Drug: Levamisole (LMS)
RxNorm normalized name: Levamisole
DrugBank: Levamisole (DB00848)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Levamisole (LMS) at four different dose levels over 3 days
Trial: 6343149
Drug: Oral etretinate,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral etretinate, 1 mg/kg b.w. for 8 weeks
Trial: 28605730
Drug: Gemcitabine (1,200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gemcitabine (1,200 mg/m2) and Vinorelbine (25 mg/m2) intravenously on days 1 and 8 every 3 weeks
Trial: 22996370
Drug: Autologous dendritic
RxNorm normalized name: COVID19 s-vax loaded autologous dendritic cell vaccine
DrugBank: COVID19 s-vax loaded autologous dendritic cell vaccine (DB15814)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Autologous dendritic cells (DC) loaded with antigens from tumor cells, injected subcutaneously in 500 µg of granulocyte‐macrophage colony stimulating factor, weekly for 3 weeks and then monthly for 5 months.
Trial: 22996370
Drug: Irradiated autologous
RxNorm normalized name: Autologous cultured fibroblasts
DrugBank: Azficel-T (DB11051)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Irradiated autologous proliferating tumor cells, injected subcutaneously in 500 µg of granulocyte‐macrophage colony stimulating factor, weekly for 3 weeks and then monthly for 5 months.
Trial: 17486281
Drug: 20 mg
RxNorm normalized name: urea 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg of tadalafil on demand
Trial: 17486281
Drug: 20 mg
RxNorm normalized name: urea 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg of tadalafil three times per week
Trial: 9801927
Drug: Low-dose heparin
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose heparin (12,500 U, subcutaneously daily) plus antianginal treatment
Trial: 1550410
Drug: Lornoxicam 12
RxNorm normalized name: lornoxicam
DrugBank: Lornoxicam (DB06725)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lornoxicam 12 mg daily
Trial: 25773712
Drug: Lixisenatide 20
RxNorm normalized name: lixisenatide 20 mcg/0.2 mL subcutaneous solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lixisenatide 20 µg
Trial: 24561125
Drug: Liraglutide 1.2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Liraglutide 1.2 mg and 1.8 mg
Trial: 23578669
Drug: Preventive treatment
RxNorm normalized name: STANNOUS FLUORIDE 0.004 g in 1 g DENTAL GEL [Enamelon Preventive Treatment]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Preventive treatment (endovascular surgery, coiling, clipping) for UIAs larger than 5 mm
Trial: 21274557
Drug: 50 mg
RxNorm normalized name: talc 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 mg sildenafil p.o.
Trial: 21274557
Drug: 100 mg
RxNorm normalized name: urea 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg sildenafil p.o.
Trial: 21274557
Drug: 10 μg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 μg iloprost inhalation
Trial: 19248129
Drug: Anakinra 50
RxNorm normalized name: ANAKINRA
DrugBank: Anakinra (DB00026)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Anakinra 50 mg
Trial: 19248129
Drug: Anakinra 150
RxNorm normalized name: ANAKINRA
DrugBank: Anakinra (DB00026)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Anakinra 150 mg
Trial: 9041991
Drug: IV IgG
RxNorm normalized name: Human IGG
DrugBank: Human immunoglobulin G (DB00028)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV IgG (Polyglobin, n = 14, total dosage: 18 mL/kg)
Trial: 9041991
Drug: IV IgGMA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV IgGMA (Pentaglobin, n = 13, total dosage: 15 mL/kg)
Trial: 27401564
Drug: Intravenous or
RxNorm normalized name: Medicated Pad or Tape
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous or oral fluconazole at 6 mg/kg of body weight twice weekly
Trial: 25762749
Drug: Varenicline (VAR)
DrugBank: Varenicline (DB01273)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Varenicline (VAR) tablets and placebo patches
Trial: 25762749
Drug: Placebo tablets
RxNorm normalized name: placebo Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo tablets and nicotine patches
Trial: 21610201
Drug: TAK-875 (25-800
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TAK-875 (25-800 mg)
Trial: 19880786
Drug: Maintain testosterone
RxNorm normalized name: Testosterone
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Maintain testosterone and estradiol at eugonadal levels for young men (GnRH agonist + testosterone gel)
Trial: 19880786
Drug: Block testosterone's
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Block testosterone's conversion to estradiol (GnRH agonist + testosterone gel + aromatase inhibitor)
Trial: 19880786
Drug: Induce hypogonadism
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Induce hypogonadism (GnRH agonist alone)
Trial: 17980667
Drug: Minocycline (up
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Minocycline (up to 400 mg/day for 9 months)
Trial: 15642073
Drug: Metformin XR
RxNorm normalized name: metformin Extended Release Suspension
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metformin XR 2000 mg once daily
Trial: 15966755
Drug: Metformin IR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metformin IR 1000 mg twice daily
Trial: 12483717
Drug: 5 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg/kg of MRA
Trial: 12483717
Drug: 10 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg/kg of MRA
Trial: 12483717
Drug: 5 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg/kg and 10 mg/kg of MRA
Trial: 10488265
Drug: Intradermal bacteriostatic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intradermal bacteriostatic 0.9% sodium chloride containing the preservative benzyl alcohol
Trial: 10488265
Drug: Intradermal lidocaine
RxNorm normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intradermal lidocaine hydrochloride 1%
Trial: 24763890
Drug: Topical cream
RxNorm normalized name: Topical Cream
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical cream containing 0.5% Aloe vera juice powder applied 3 times per day for 6 weeks